A patient previously treated with ALK inhibitors for central nervous system lesions from ALK rearranged lung cancer: a case report

BACKGROUND: Patients with anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC) are now preferentially treated with tyrosine kinase inhibitors (TKIs). However, patients treated with ALK inhibitors end up with acquired resistance. CASE PRESENTATION: We present a patient with...

Descripción completa

Detalles Bibliográficos
Autores principales: Kashima, Jumpei, Okuma, Yusuke, Hishima, Tsunekazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066989/
https://www.ncbi.nlm.nih.gov/pubmed/27785052
http://dx.doi.org/10.2147/OTT.S112833

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066989/
https://www.ncbi.nlm.nih.gov/pubmed/27785052
http://dx.doi.org/10.2147/OTT.S112833

Ejemplares similares